You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 120 No. 6, June 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Abstract
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (498)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Glaucoma
 •Ophthalmological Disorders, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?


The Ocular Hypertension Treatment Study

Baseline Factors That Predict the Onset of Primary Open-Angle Glaucoma

Mae O. Gordon, PhD; Julia A. Beiser, MS; James D. Brandt, MD; Dale K. Heuer, MD; Eve J. Higginbotham, MD; Chris A. Johnson, PhD; John L. Keltner, MD; J. Philip Miller, AB; Richard K. Parrish II, MD; M. Roy Wilson, MD; Michael A. Kass, MD; for the Ocular Hypertension Treatment Study Group

Arch Ophthalmol. 2002;120:714-720.

ABSTRACT

Background  The Ocular Hypertension Treatment Study (OHTS) has shown that topical ocular hypotensive medication is effective in delaying or preventing the onset of primary open-angle glaucoma (POAG) in individuals with elevated intraocular pressure (ocular hypertension) and no evidence of glaucomatous damage.

Objective  To describe baseline demographic and clinical factors that predict which participants in the OHTS developed POAG.

Methods  Baseline demographic and clinical data were collected prior to randomization except for corneal thickness measurements, which were performed during follow-up. Proportional hazards models were used to identify factors that predicted which participants in the OHTS developed POAG.

Results  In univariate analyses, baseline factors that predicted the development of POAG included older age, race (African American), sex (male), larger vertical cup-disc ratio, larger horizontal cup-disc ratio, higher intraocular pressure, greater Humphrey visual field pattern standard deviation, heart disease, and thinner central corneal measurement. In multivariate analyses, baseline factors that predicted the development of POAG included older age, larger vertical or horizontal cup-disc ratio, higher intraocular pressure, greater pattern standard deviation, and thinner central corneal measurement.

Conclusions  Baseline age, vertical and horizontal cup-disc ratio, pattern standard deviation, and intraocular pressure were good predictors for the onset of POAG in the OHTS. Central corneal thickness was found to be a powerful predictor for the development of POAG.



INTRODUCTION
 Jump to Section
 •Top
 •Introduction
 •Participants and methods
 •Results
 •Comment
 •Author information
 •References

THE OCULAR Hypertension Treatment Study (OHTS) was a multicenter randomized trial designed to evaluate the safety and efficacy of topical ocular hypotensive medication in delaying or preventing the onset of primary open-angle glaucoma (POAG) in individuals with elevated intraocular pressure (IOP) and no detectable glaucomatous damage. The results of the OHTS are described in detail in our companion article.1

The cumulative probability of developing POAG was reduced by 60% among participants randomized to receive topical ocular hypotensive medication compared with those randomized to observation (hazard ratio, 0.40; 95% confidence interval [CI], 0.27-0.59). At 60 months, the cumulative probability of developing POAG was 4.4% in the medication group and 9.5% in the observation group.

During the planning phase of the OHTS, we identified several baseline demographic and clinical factors that might predict which participants in the trial would develop POAG. If some of these factors proved to be good predictors, clinicians could use this information to decide the appropriateness of initiating, continuing, or discontinuing topical ocular hypotensive medication in patients with ocular hypertension.


PARTICIPANTS AND METHODS
 Jump to Section
 •Top
 •Introduction
 •Participants and methods
 •Results
 •Comment
 •Author information
 •References

STUDY DESIGN

The protocol is described in detail in the study manual,2 in the baseline design article,3 and on the World Wide Web at http://www.vrcc.wustl.edu. The protocol was approved by the institutional review board of each participating clinic. In brief, 1636 participants who had ocular hypertension, with an IOP between 24 mm Hg and 32 mm Hg in one eye and between 21 mm Hg and 32 mm Hg in the other eye and no evidence of glaucomatous damage, were randomized to either observation or treatment with commercially available topical ocular hypotensive medication. The goal of treatment with topical ocular hypotensive medication was to achieve an IOP of 24 mm Hg or less and a minimum 20% reduction from the average of the qualifying IOP and IOP at the baseline randomization visit, except that an IOP of less than 18 mm Hg was not required. The primary outcome was the development of reproducible visual field abnormality or clinically significant reproducible optic disc deterioration attributable to POAG. Abnormalities were determined by masked certified readers at the Visual Field and Optic Disc Reading Centers, and attribution to POAG was decided by the masked Endpoint Committee.

Baseline demographic and clinical information was collected for each participant prior to randomization. The baseline clinical examination included refraction, best-corrected visual acuity, full-threshold white-on-white Humphrey 30-2 visual field tests, IOP measurement, a dilated fundus examination, and stereoscopic optic disc photographs. Myopia was defined as a spherical equivalent of -1.0 diopter (D) or more. Horizontal and vertical cup-disc ratios by contour were estimated visually from stereoscopic optic disc photographs by masked certified readers in the Optic Disc Reading Center.4 Information collected by participant report included ocular and medical history, family history of glaucoma, current use of medications including oral calcium channel blockers, and oral {beta}-adrenergic antagonists. Medical history was obtained by asking, "Has a doctor ever told you that you have any of the following conditions?" and reading a list of medical conditions. Family history of glaucoma was determined by asking, "Do any of your blood relatives (biological mother or father, biological brother or sister, biological aunt or uncle, or biological grandmother or grandfather) have glaucoma?" A first-degree relative was defined as a biological parent or sibling.

During the planning phase of the OHTS, we identified several factors as possible predictors for the development of POAG. These included age, self-identified race, sex, vertical and horizontal cup-disc ratio, IOP, family history of glaucoma, visual field indexes, myopia, heart disease, high blood pressure, low blood pressure, treatment of medical conditions with oral calcium channel blockers or oral {beta}-adrenergic antagonists, cerebrovascular accident, diabetes mellitus, and migraine. During the course of the OHTS, increasing information indicated that thick corneas could cause overestimation of the true IOP and that individuals classified as having ocular hypertension had thicker corneas on average. We began to collect central corneal thickness measurements in early 1999, about 2 years after randomization of the last participant. The protocol for the measurement of central corneal thickness is described in a previously published article.5 New conditions or signs that occurred during follow-up, such as optic disc hemorrhage, are not included in this article.

STATISTICAL ANALYSIS

For eye-specific variables, we calculated the mean for each eye and then averaged these 2 values to determine the baseline predictive factor. The IOP predictive factor was calculated from 4 to 6 baseline IOP measurements per eye. The visual field predictive factors (mean deviation, pattern standard deviation, and corrected pattern standard deviation) were calculated from 2 normal and reliable baseline visual fields per eye. The central corneal thickness predictive factor was calculated from 5 measurements per eye obtained during the same visit. Cox proportional hazards models as implemented in the PHREG program in the SAS statistical software (SAS Institute Inc, Cary, NC) were used to estimate and test factors for their association with the development of POAG. The analysis sample for the proportional hazards models consisted of 125 randomized participants who developed POAG and 1493 randomized participants with at least 1 follow-up visit (18 of 1636 participants did not have any follow-up visits) who did not develop POAG. The analysis data set included all data through November 8, 2001, as recommended by the Data and Safety Monitoring Committee. Median participant follow-up was 72 months. A parsimonious model was selected using the score criterion in PHREG for comparing models containing 1 predictive factor with those containing combinations of all predictive factors. We report hazard ratios from univariate models, which do not adjust for the presence of other factors, as well as adjusted hazard ratios from the multivariate Cox proportional hazards models. Univariate and multivariate hazard ratios for developing POAG and their 95% CIs are reported for each putative predictive factor. Statistical significance was defined as P<.05.


RESULTS
 Jump to Section
 •Top
 •Introduction
 •Participants and methods
 •Results
 •Comment
 •Author information
 •References

Baseline demographic and clinical factors of participants who did and did not develop POAG in the OHTS are reported in Table 1 and Table 2. The percentages in Table 1 were calculated by dividing the number of participants who developed POAG by the number of randomized participants with at least 1 follow-up visit (1618). These values are not adjusted for duration of follow-up. Corneal thickness measurements, which began in 1999, were completed in 1398 participants.


View this table:
[in this window]
[in a new window]
Table 1. Putative Baseline Demographic and Clinical Predictors by POAG Status*



View this table:
[in this window]
[in a new window]
Table 2. Baseline Age and Putative Ocular Predictors by POAG Status*


Univariate and multivariate Cox proportional hazards models were evaluated in the observation group alone and in the entire study sample using randomization group as a stratification variable. Both analyses identified similar predictive factors; therefore, we report the results from models based on the entire sample because that approach provides greater statistical power.

Univariate and multivariate hazard ratios with 95% CIs are reported for each putative predictive factor for the development of POAG (Table 3). In univariate analyses, baseline factors significantly predictive of the development of POAG were older age, race (African American), sex (male), higher IOP, larger vertical cup-disc ratio, larger horizontal cup-disc ratio, greater pattern standard deviation, heart disease, and thinner central corneal measurement. Factors significantly predictive of the development of POAG in both the univariate and multivariate models included older age, higher IOP, greater pattern standard deviation, thinner central corneal measurement, and larger vertical cup-disc ratio. Although horizontal and vertical cup-disc ratios were highly correlated (r = 0.92), vertical cup-disc ratio was a slightly better predictor for the development of POAG than horizontal cup-disc ratio. Therefore, vertical cup-disc ratio was included in the multivariate risk model, and horizontal cup-disc ratio was not.


View this table:
[in this window]
[in a new window]
Table 3. Univariate and Multivariate Hazard Ratios and 95% Confidence Intervals for the Development of POAG*


A history of diabetes mellitus appeared to be significantly protective against developing POAG in both univariate and multivariate models. Among the 191 participants who reported a history of diabetes mellitus at baseline, 6 (3.1%) developed POAG compared with 119 (8.3%) of 1427 participants who did not report a history of diabetes mellitus. The univariate hazard ratio for diabetes mellitus was 0.40 (95% CI, 0.18-0.92), and the multivariate hazard ratio was 0.37 (95% CI, 0.15-0.90).

Baseline factors associated with developing POAG that were statistically significant in the univariate model but not in the multivariate model were race, heart disease, and sex (male). In the univariate model, race (African American) was associated with a 59% increase in the risk of developing POAG (hazard ratio, 1.59; 95% CI, 1.09-2.32). In this study, African American participants had a larger mean ± SD baseline vertical cup-disc ratio (0.45 ± 0.18) compared with other participants (0.37 ± 0.20) and a thinner mean ± SD central corneal measurement (554.9 ± 38.5 µm) than other participants (578.3 ± 36.5 µm). The inclusion of either baseline vertical cup-disc ratio or corneal thickness caused race to become statistically nonsignificant in the multivariate model.

The OHTS enrolled 56 participants who identified themselves as Hispanic. Eight (14.3%) of these 56 participants (95% CI, 5%-23%) developed POAG during follow-up. Hispanic participants resembled the other participants in terms of demographic and baseline clinical features. Because of the small sample size, we did not include Hispanic ethnic identity as a separate predictive factor and grouped Hispanic participants with "others" in the analyses.

Baseline factors that were not associated with the risk of developing POAG in both univariate and multivariate models included family history of glaucoma (first-degree relative or any relative), mean deviation, corrected pattern standard deviation, myopia, migraine, cerebrovascular accident, high blood pressure, low blood pressure, and use of oral {beta}-adrenergic antagonists or oral calcium channel blockers. No association with POAG was found for myopia of -1.0 D or less, greater than -1.0 D to -3.0 D (moderate myopia), or greater than -3.0 D (high myopia).

A thinner central corneal measurement predicted the development of POAG in both univariate and multivariate models. Among participants who developed POAG, the mean ± SD central corneal thickness was 553.1 ± 38.8 µm compared with 574.3 ± 37.8 µm among those who did not develop POAG. We examined whether the effect of corneal thickness on the development of POAG was present across the range of corneal thickness measurements observed in the OHTS. We divided the entire sample into 3 approximately equal-sized groups of participants (n = 450-480) with corneal thickness measurements of 555 µm or less (mean, 530.8 µm), greater than 555 µm to less than or equal to 588 µm (mean, 571.7 µm), and more than 588 µm (mean, 613.5 µm). For each group, we computed the multivariate hazard ratio for the development of POAG using the group with the thickest corneas as a reference. Compared with the participants with the thickest corneas (>588 µm), participants with intermediate central corneal measurements (>555 µm to <=588 µm) had a hazard ratio of 1.7 (95% CI, 0.97-3.0), and participants with the thinnest central corneal measurements (<=555 µm) had a hazard ratio of 3.4 (95% CI, 2.1-5.6). Similar analyses conducted using 4 to 8 categories of corneal thickness supported the conclusion that the risk of developing POAG was inversely correlated with central corneal thickness, with no apparent threshold effect.

Next we examined whether the effect of corneal thickness on the development of POAG was present across the range of baseline IOP observed in the OHTS. The entire sample was divided into 3 approximately equal groups of participants (n = 531-567) with an IOP of 23.75 mm Hg or less (mean, 22.2 mm Hg), greater than 23.75 mm Hg to less than or equal to 25.75 mm Hg (mean, 24.8 mm Hg), and more than 25.75 mm Hg (mean, 27.9 mm Hg). For each IOP group, we computed a multivariate hazard ratio for participants with the thinnest, intermediate, and thickest central corneal measurements as described previously. The risk of developing POAG was highest among participants with the thinnest central corneal measurements within each IOP group. The relationship between corneal thickness and risk of developing POAG did not differ substantially between the 3 IOP groups (P = .14). Figure 1 illustrates the percentage of participants in the observation group who developed POAG, grouped by central corneal measurements and IOP.



View larger version (38K):
[in this window]
[in a new window]
Figure 1. The percentage of participants in the observation group who developed primary open-angle glaucoma (median follow-up, 72 months) grouped by baseline intraocular pressure (IOP) of <=23.75 mm Hg, >23.75 mm Hg to <=25.75 mm Hg, and >25.75 mm Hg and by central corneal thickness measurements of <=555 µm, >555 µm to <=588 µm, and >588 µm. These percentages are not adjusted for length of follow-up. The means are not identical to those given in the text, which includes all participants in the Ocular Hypertension Treatment Study rather than just the observation group.


We then examined whether the effect of central corneal thickness on the development of POAG was present across the range of baseline vertical cup-disc ratios observed in the OHTS. We divided the entire sample into 3 approximately equal groups of participants (n = 524-569) with baseline vertical cup-disc ratios of 0.30 or less (mean, 0.16), greater than 0.30 to less than 0.50 (mean, 0.40), and 0.50 or higher (mean, 0.60). For each vertical cup-disc ratio group, we computed a multivariate hazard ratio for participants with the thinnest, intermediate, and thickest central corneal measurements. The risk of developing POAG was highest among participants with the thinnest central corneal measurements within each vertical cup-disc ratio group. The relationship between corneal thickness and the risk of developing POAG did not differ substantially between the 3 cup-disc ratio groups (P = .32). Figure 2 illustrates the percentage of participants in the observation group who developed POAG, grouped by central corneal measurements and vertical cup-disc ratio.



View larger version (39K):
[in this window]
[in a new window]
Figure 2. The percentage of participants in the observation group who developed primary open-angle glaucoma (median follow-up, 72 months) grouped by baseline vertical cup-disc (VCD) ratios of <=0.30, >0.30 to <0.50, and >=0.50 and by central corneal thickness measurements of <=555 µm, >555 µm to <=588 µm, and >588 µm. The means are not identical to those given in the text, which includes all participants in the Ocular Hypertension Treatment Study rather than just the observation group.


We were concerned that the apparent predictive power of central corneal thickness on the development of POAG could be explained by the correlation between corneal thickness and other predictors of POAG. However, we found little evidence for this. Pearson correlation coefficients for the association between corneal thickness and other baseline factors were as follows: age (r = -0.14), vertical cup-disc ratio (r = -0.12), IOP (r = -0.03), pattern standard deviation (r = -0.07), and mean deviation (r = 0.01). The correlations between central corneal thickness and these baseline factors were also computed using the Kendall {tau}-b and Spearman rank order tests, with similar results.


COMMENT
 Jump to Section
 •Top
 •Introduction
 •Participants and methods
 •Results
 •Comment
 •Author information
 •References

Almost all previous studies of risk factors for POAG collected risk factor data retrospectively or at the time that POAG was ascertained.6-17 In the OHTS, risk factors were measured at baseline prior to the onset of POAG, so that predictive factors could be differentiated with greater precision. Only corneal thickness was measured after randomization. Stringent eligibility criteria ensured that each case of POAG detected during follow-up was a new case and not one that had escaped detection at baseline. Determination of abnormality was made independently by masked certified readers at the reading centers, and confirmation of abnormality required multiple tests separated by several weeks or months. Attribution of abnormality to POAG was made by the masked Endpoint Committee. Thus, the OHTS protocol ensured that incident cases of POAG were truly new cases and that the diagnosis of POAG was made with high specificity.

The OHTS confirmed that age, cup-disc ratio, and IOP are predictive factors for the development of POAG in individuals with ocular hypertension. Similar findings have been reported previously in population surveys, case-control studies, and prospective studies. Leske,18 Tielsch,19 and Wilson and Martone20 have published detailed articles on risk factors for glaucoma. The predictive factors identified in our study are most likely to be helpful for assessing the risk of patients who resemble the OHTS participants; that is, individuals who have ocular hypertension, an IOP between 24 and 32 mm Hg, and no evidence of glaucomatous damage.

Some scientists might argue that a larger cup-disc ratio is not a risk factor for developing POAG but rather an indicator of early glaucomatous damage. However, when a clinician examines a patient for the first time, there is no way to determine whether the cup-disc ratio observed has been stable during the patient's lifetime or has enlarged as part of the disease process, assuming that no previous photographs or measurements are available for comparison. A patient with a large cup-disc ratio unaltered by glaucoma may be at greater risk for developing POAG. Thus, we decided to include baseline cup-disc ratio in the predictive models. A similar reasoning process was followed to include baseline visual field indexes in these models as well.

In the OHTS, 3 putative predictive factors (race, sex, and heart disease) were identified in univariate analyses but were not statistically significant in multivariate models. The statistical power to detect the association between these factors and the development of POAG ranged from 0.50 to 0.90, assuming conventional levels of statistical significance. Some of these factors might have been statistically significant in multivariate models if a greater number of participants with the risk factor had been enrolled (eg, only 101 participants reported heart disease at baseline) or if a larger number of incident POAG cases had occurred. On the other hand, the number of incident POAG cases in the OHTS (125 of 1636 participants with ocular hypertension) exceeds that in previous reports of large prospective studies of glaucoma, including the Iowa Study (4 eyes of 1628 individuals),21 the Collaborative Glaucoma Study (93 eyes of 5886 subjects),22 the Dalby Study (12 eyes of 599 individuals),23 and the Barbados Incidence Study of Eye Diseases (67 of 3427 participants).24

Univariate analyses indicated that self-identified African American participants had a 59% increase in the risk of developing POAG. Many studies have reported a substantially higher prevalence and incidence of POAG in black individuals compared with white individuals.11-12,24-26 However, African American participants in the OHTS had thinner central corneal measurements and larger baseline vertical cup-disc ratios. In multivariate analyses that adjusted for these factors, race was no longer a statistically significant predictor.

In the OHTS, 8 of 56 Hispanic participants developed POAG. Although this small sample size prevented detailed analysis, the results were consistent with a recent population survey that found a higher prevalence of POAG in Hispanic subjects.27

Family history of glaucoma is a well-established risk factor for POAG.28-31 Forty-seven (8.5%) of 553 participants who reported at least 1 first-degree relative with glaucoma developed POAG, compared with 78 (7.3%) of 1065 who did not. Of all OHTS participants, 42% reported either a first-degree relative or any relative with glaucoma. No attempt was made to verify the participants' reports or to corroborate the diagnoses with family members or clinicians. The high proportion of participants who reported a family history of glaucoma suggests that this condition is not always distinguished from ocular hypertension. Population surveys and genetic studies are likely to provide stronger tests of the heritability of POAG.

In the OHTS, male sex predicted the development of POAG in the univariate analyses but was of borderline significance in multivariate models. Other studies of the relationship between sex and POAG have yielded conflicting results, with some studies finding men at higher risk,12, 31-32 some finding women at higher risk,33 and some finding no association.9, 19, 34

Myopia was not predictive of the development of POAG in the OHTS. In contrast, several well-performed case-control and population-based studies have reported an association between myopia, particularly high myopia, and POAG.35-37

Low perfusion pressure has been associated with POAG30 and may be an important consideration in the decision to treat elevated IOP.38 However, in the OHTS, a history of low blood pressure at baseline was ascertained only by self-report. We did not perform blood pressure readings and are unable to test this interesting hypothesis.

In both our univariate and multivariate analyses, a history of diabetes mellitus at baseline appeared to be protective against developing POAG. This contradicts all previously published studies, which either found that diabetes is associated with POAG39-41 or that there is no association.19, 30, 33, 42-43 We did not confirm the diagnosis of diabetes mellitus in OHTS participants with blood tests or medication use. Because individuals with diabetic retinopathy were excluded from the OHTS, we probably enrolled an unrepresentative group of patients with diabetes. These factors may explain the paradoxical relationship between diabetes mellitus and POAG in the OHTS.

We found that small differences in pattern standard deviation at baseline predicted the development of POAG, even among participants who had normal and reliable results on Humphrey 30-2 visual field tests. Such small differences can be detected only by taking an average from multiple visual fields, as was done in the OHTS. The visual field predictive factor was computed from 4 normal and reliable visual field test results (2 from each eye) per participant. It is unlikely that pattern standard deviation would be a useful predictive factor in general practice.

To our knowledge, the OHTS is the first study to prospectively document that a thinner central corneal measurement predicts the development of POAG. Corneal thickness appeared to be a strong predictive factor for the development of POAG, even after adjusting for the effects of baseline age, IOP, vertical cup-disc ratio, and pattern standard deviation. Participants with a corneal thickness of 555 µm or less had a 3-fold greater risk of developing POAG compared with participants who had a corneal thickness of more than 588 µm. This inverse relationship was found across the ranges of baseline IOP and baseline vertical cup-disc ratios. It is well known that corneal thickness influences the measurement of IOP. Eyes with thicker corneas have a true IOP that is lower than the measured IOP. Conversely, eyes with thin corneas have a true IOP that is greater than the measured IOP. Thus, individuals with thicker corneas may be misclassified as having ocular hypertension. Cross-sectional studies have documented that central corneal thickness is greater in individuals with measured ocular hypertension compared with normotensive individuals or those with glaucoma.44-51

It is likely that the predictive power of corneal thickness is due to its effect on the measured IOP. However, we cannot exclude the possibility that corneal thickness is related to other factors affecting susceptibility to glaucomatous damage. Baseline IOP was not correlated with corneal thickness in the OHTS, partly because of the narrow range of IOP. We did not use available formulas to correct the IOP for corneal thickness because they are theoretical in nature52 or derived from small samples with limited racial variation.53-55 In the OHTS, the mean central corneal thickness among African Americans was 23.5 µm thinner than that of other participants.5 The central corneal thickness of the African American participants more closely resembles the norm, whereas the other participants had thicker corneas than the norm.47-51 We conclude that central corneal thickness provides new information about the risk of developing POAG, and we recommend its measurement in the clinical evaluation of patients with ocular hypertension.

In summary, the OHTS data suggest that a clinician caring for a patient with ocular hypertension can assess that individual's risk of developing POAG by considering age, IOP, cup-disc ratio, and central corneal thickness. By combining these factors, the clinician can identify patients at moderate to high risk for developing POAG and who are more likely to benefit from early medical treatment.


AUTHOR INFORMATION
 Jump to Section
 •Top
 •Introduction
 •Participants and methods
 •Results
 •Comment
 •Author information
 •References

Submitted for publication March 6, 2002; final revision received April 10, 2002; accepted April 10, 2002.

This study was supported by grants EY09341 and EY09307 from the National Eye Institute and the National Center for Minority Health and Health Disparities, National Institutes of Health, Bethesda, Md; Merck Research Laboratories, White House Station, NJ; and by an unrestricted grant from Research to Prevent Blindness, New York, NY.

Drs Gordon and Kass take responsibility for authorship, financial disclosure, and copyright transfer for the group.

Corresponding author and reprints: Mae O. Gordon, PhD, OHTS Coordinating Center, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, Box 8203, 660 South Euclid, St Louis, MO 63110 (e-mail: mae{at}vrcc.wustl.edu).

From the Department of Ophthalmology and Visual Sciences (Drs Gordon and Kass and Ms Beiser) and Division of Biostatistics (Mr Miller), Washington University School of Medicine, St Louis, Mo; Department of Ophthalmology, University of California, Davis (Drs Brandt and Keltner); Department of Ophthalmology, Medical College of Wisconsin, Milwaukee (Dr Heuer); Maryland Center for Eye Care Associates and the Department of Ophthalmology, University of Maryland, Baltimore (Dr Higginbotham); Devers Eye Institute, Portland, Ore (Dr Johnson); Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Fla (Dr Parrish); and Creighton University School of Medicine, Omaha, Neb (Dr Wilson).


REFERENCES
 Jump to Section
 •Top
 •Introduction
 •Participants and methods
 •Results
 •Comment
 •Author information
 •References

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713. FREE FULL TEXT
2. Gordon MO, Kass MA and the Ocular Hypertension Treatment Study Group (OHTS). Manual of Procedures. Springfield, Va: National Technical Information Service; 1997. Publication PB97-148308NZ.
3. Gordon MO, Kass MA for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573-583. FREE FULL TEXT
4. Feuer WJ, Parrish II RK, Schiffman JC, et al. The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. Am J Ophthalmol. 2002;133:19-28. FULL TEXT | ISI | PUBMED
5. Brandt JD, Beiser JA, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001;108:1779-1788. FULL TEXT | ISI | PUBMED
6. Hollows FC, Graham PA. Intra-ocular pressure, glaucoma, and glaucoma suspects in a defined population. Br J Ophthalmol. 1966;50:570-586. FREE FULL TEXT
7. Kahn HA, Milton RC. Alternative definitions of open-angle glaucoma: effect on prevalence and associations in the Framingham eye study. Arch Ophthalmol. 1980;98:2172-2179. FREE FULL TEXT
8. Tielsch JM, Sommer A, Witt K, Katz J, Royall RM. Blindness and visual impairment in an American urban population: the Baltimore Eye Survey. Arch Ophthalmol. 1990;108:286-290. FREE FULL TEXT
9. Klein BEK, Klein R, Sponsel WE, et al. Prevalence of glaucoma: the Beaver Dam Eye Study. Ophthalmology. 1992;99:1499-1504. ISI | PUBMED
10. Coffey M, Reidy A, Wormold R, Xian WX, Wright L, Courtney P. Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol. 1993;77:17-21. FREE FULL TEXT
11. Mason RP, Kosoko O, Wilson MR, et al. National survey of the prevalence and risk factors of glaucoma in St Lucia, West Indies, I: prevalence findings. Ophthalmology. 1989;96:1363-1368. ISI | PUBMED
12. Leske MC, Connell AM, Schachat AP, Hyman L for the Barbados Eye Study Group. The Barbados Eye Study: prevalence of open angle glaucoma. Arch Ophthalmol. 1994;112:821-829. FREE FULL TEXT
13. Shiose Y, Kitazawa Y, Tsukahara S, et al. Epidemiology of glaucoma in Japan: a nationwide glaucoma survey. Jpn J Ophthalmol. 1991;35:133-155. PUBMED
14. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands: the Rotterdam Study. Ophthalmology. 1994;101:1851-1855. ISI | PUBMED
15. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia: the Blue Mountains Eye Study. Ophthalmology. 1996;103:1661-1669. ISI | PUBMED
16. Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology. 1998;105:733-739. FULL TEXT | ISI | PUBMED
17. Bonomi L, Marchini G, Marraffa M, et al. Prevalence of glaucoma and intraocular pressure distribution in a defined population: the Egna-Neumarkt Study. Ophthalmology. 1998;105:209-215. FULL TEXT | ISI | PUBMED
18. Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol. 1983;118:166-191. FREE FULL TEXT
19. Tielsch JM. The epidemiology and control of open angle glaucoma: a population-based perspective. Annu Rev Public Health. 1996;17:121-136. ISI | PUBMED
20. Wilson RM, Martone JF. The epidemiology of chronic open-angle glaucoma and ocular hypertension. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas: A Multi-volume Reference. St Louis, Mo: Mosby-Year Book; 1996:753-768.
21. Armaly MF. Ocular pressure and visual fields: a ten-year follow-up study. Arch Ophthalmol. 1969;81:25-40. FREE FULL TEXT
22. Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of the collaborative glaucoma study, I: summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol. 1980;98:2163-2171. FREE FULL TEXT
23. Bengtsson B. Manifest glaucoma in the aged, I: occurrence nine years after a population survey. Acta Ophthalmol (Copenh). 1981;59:321-331.
24. Leske MC, Connell AM, Wu SY, et al for the Barbados Eye Studies Group. Incidence of open-angle glaucoma: the Barbados Eye Studies. Arch Ophthalmol. 2001;119:89-95. FREE FULL TEXT
25. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA. 1991;266:369-374. FREE FULL TEXT
26. Buhrmann RR, Quigley HA, Barron Y, West SK, Oliva MS, Mmbaga BB. Prevalence of glaucoma in a rural East African population. Invest Ophthalmol Vis Sci. 2000;41:40-48. FREE FULL TEXT
27. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119:1819-1826. FREE FULL TEXT
28. Armaly MF. On the distribution of applanation pressure, I: statistical features and the effect of age, sex, and family history of glaucoma. Arch Ophthalmol. 1965;73:11-18.
29. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Family history and risk of primary open-angle glaucoma: the Baltimore Eye Survey. Arch Ophthalmol. 1994;112:69-73. FREE FULL TEXT
30. Leske MC, Nemesure B, He Q, Wu SY, Hejtmancik J, Hennis A. Patterns of open-angle glaucoma in the Barbados Family Study. Ophthalmology. 2001;108:1015-1022. FULL TEXT | ISI | PUBMED
31. Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the Visual Impairment Project. Ophthalmology. 2001;108:1966-1972. FULL TEXT | ISI | PUBMED
32. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24(suppl):335-610.
33. Bengtsson B. The prevalence of glaucoma. Br J Ophthalmol. 1981;65:46-49. FREE FULL TEXT
34. Quigley HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol. 1994;112:644-649. FREE FULL TEXT
35. Ponte F, Giuffre G, Giammanco R, Dardononi G. Risk factors of ocular hypertension and glaucoma: the Casteldaccia Eye Study. Doc Ophthalmol. 1994;85:203-210. FULL TEXT | ISI | PUBMED
36. Mitchell P, Hourihan F, Sandbach J, Wang JJ. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology. 1999;106:2010-2015. FULL TEXT | ISI | PUBMED
37. Perkins ES, Phelps CD. Open angle glaucoma, ocular hypertension, low-tension glaucoma, and refraction. Arch Ophthalmol. 1982;100:1464-1467. FREE FULL TEXT
38. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma: a population-based assessment. Arch Ophthalmol. 1995;113:216-221. FREE FULL TEXT
39. Nielsen NV. The prevalence of glaucoma and ocular hypertension in type I and 2 diabetes mellitus: an epidemiological study of diabetes mellitus on the island of Falster, Denmark. Acta Ophthalmol (Copenh). 1983;61:662-672.
40. Klein BEK, Klein R, Jensen SC. Open-angle glaucoma and older-onset diabetes: the Beaver Dam Eye Study. Ophthalmology. 1994;101:1173-1177. ISI | PUBMED
41. Dielemans I, de Jong PT, Stolk R, Vingerling JR, Grobbee DE, Hofman A. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population: the Rotterdam Study. Ophthalmology. 1996;8:1271-1275.
42. Tielsch JM, Katz J, Quigley HA, Javitt JC, Sommer A. Diabetes and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology. 1995;102:48-53. ISI | PUBMED
43. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study II: association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol. 1977;106:33-41. FREE FULL TEXT
44. Argus WA. Ocular hypertension and central corneal thickness. Ophthalmology. 1995;102:1810-1812. ISI | PUBMED
45. Herndon LW, Choudhri SA, Cox T, Damji KF, Shields MB, Allingham RR. Central corneal thickness in normal, glaucomatous, and ocular hypertensive eyes. Arch Ophthalmol. 1997;115:1137-1141. FREE FULL TEXT
46. Herman DC, Hodge DO, Bourne WM. Increased corneal thickness in patients with ocular hypertension. Arch Ophthalmol. 2001;119:334-336. FREE FULL TEXT
47. Emara BY, Tingey DP, Probst LE, Motolko MA. Central corneal thickness in low-tension glaucoma. Can J Ophthalmol. 1999;34:319-324. ISI | PUBMED
48. Copt RP, Thomas R, Mermoud A. Central thickness in ocular hypertension, primary open-angle glaucoma, and normal tension glaucoma. Arch Ophthalmol. 1999;117:14-16. FREE FULL TEXT
49. Morad Y, Sharon E, Hefetz L, Nemet P. Corneal thickness and curvature in normal-tension glaucoma. Am J Ophthalmol. 1998;125:164-168. FULL TEXT | ISI | PUBMED
50. Alsbirk PH. Corneal thickness, I: age variation, gender difference, and oculometric correlations. Acta Ophthalmol (Copenh). 1978;56:95-104. PUBMED
51. Wolfs RC, Klaver CC, Vingerling JR, Grobbee DE, Hofman A, de Jong PT. Distribution of central corneal thickness and its association with intraocular pressure: the Rotterdam Study. Am J Ophthalmol. 1997;123:767-772. ISI | PUBMED
52. Orssengo GJ, Pye DC. Determination of the true intraocular pressure and modulus of elasticity of the human cornea in vivo. Bull Math Biol. 1999;61:551-572. FULL TEXT | ISI | PUBMED
53. Ehlers N, Hansen FK, Aasved H. Biometric correlations of corneal thickness. Acta Ophthalmol (Copenh). 1975;53:652-659. PUBMED
54. Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol. 2000;44:367-408. FULL TEXT | ISI | PUBMED
55. Whitacre MM, Stein RA, Hassanein K. The effect of corneal thickness on applanation tonometry. Am J Ophthalmol. 1993;115:592-596. ISI | PUBMED


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Is a History of Diabetes Mellitus Protective Against Developing Primary Open-angle Glaucoma?
Mae O. Gordon, Julia A. Beiser, Michael A. Kass, and for the Ocular Hypertension Treatment Study Group
Arch Ophthalmol. 2008;126(2):280-281.
EXTRACT | FULL TEXT  

Central Corneal Thickness and Optic Disc Hemorrhages: The Beijing Eye Study
Liang Xu, Haitao Zhang, Ya Xing Wang, and Jost B. Jonas
Arch Ophthalmol. 2008;126(3):435-436.
EXTRACT | FULL TEXT  

Diabetes and Glaucoma
Michael A. Kass, Mae O. Gordon, and for the Ocular Hypertension Treatment Study Group
Arch Ophthalmol. 2008;126(5):746-747.
EXTRACT | FULL TEXT  

Can Diabetes Be Good for Glaucoma? Why Can’t We Believe Our Own Eyes (or Data)?
Harry A. Quigley
Arch Ophthalmol. 2009;127(2):227-229.
EXTRACT | FULL TEXT  

Central Corneal Thickness and Thickness of the Lamina Cribrosa and Peripapillary Sclera in Monkeys
Jost B. Jonas, Sohan Singh Hayreh, and Yong Tao
Arch Ophthalmol. 2009;127(10):1395-1396.
EXTRACT | FULL TEXT  

RELATED ARTICLES

The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma
Michael A. Kass, Dale K. Heuer, Eve J. Higginbotham, Chris A. Johnson, John L. Keltner, J. Philip Miller, Richard K. Parrish II, M. Roy Wilson, Mae O. Gordon, and for the Ocular Hypertension Treatment Study Group
Arch Ophthalmol. 2002;120(6):701-713.
ABSTRACT | FULL TEXT  

Answers From the Ocular Hypertension Treatment Study
Paul Palmberg
Arch Ophthalmol. 2002;120(6):829-830.
EXTRACT | FULL TEXT  

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2002;120(6):876-877.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Major Genetic Effects in Glaucoma: Commingling Analysis of Optic Disc Parameters in an Older Australian Population
van Koolwijk et al.
IOVS 2009;50:5275-5280.
ABSTRACT | FULL TEXT  

Scleral Biomechanics in the Aging Monkey Eye
Girard et al.
IOVS 2009;50:5226-5237.
ABSTRACT | FULL TEXT  

Optic Disc and Visual Field Changes after Trabeculectomy
Kotecha et al.
IOVS 2009;50:4693-4699.
ABSTRACT | FULL TEXT  

Prediction of Functional Loss in Glaucoma From Progressive Optic Disc Damage
Medeiros et al.
Arch Ophthalmol 2009;127:1250-1256.
ABSTRACT | FULL TEXT  

Risk Factors for Normal-Tension Glaucoma Among Subgroups of Patients
Park et al.
Arch Ophthalmol 2009;127:1275-1283.
ABSTRACT | FULL TEXT  

Diabetes, Metabolic Abnormalities, and Glaucoma: The Singapore Malay Eye Study
Tan et al.
Arch Ophthalmol 2009;127:1354-1361.
ABSTRACT | FULL TEXT  

Progressive Optic Disc Change: Implications for Clinical Practice and Trial Design
Chauhan
Arch Ophthalmol 2009;127:1382-1383.
FULL TEXT  

Central Corneal Thickness and Thickness of the Lamina Cribrosa and Peripapillary Sclera in Monkeys
Jonas et al.
Arch Ophthalmol 2009;127:1395-1396.
FULL TEXT  

Heritability of Central Corneal Thickness in Nuclear Families
Landers et al.
IOVS 2009;50:4087-4090.
ABSTRACT | FULL TEXT  

The Relationship of Intraocular Pressure with Age, Systolic Blood Pressure, and Central Corneal Thickness in an Asian Population
Wong et al.
IOVS 2009;50:4097-4102.
ABSTRACT | FULL TEXT  

Nipradilol and Timolol Induce Foxo3a and Peroxiredoxin 2 Expression and Protect Trabecular Meshwork Cells from Oxidative Stress
Miyamoto et al.
IOVS 2009;50:2777-2784.
ABSTRACT | FULL TEXT  

Interactions between Geometry and Mechanical Properties on the Optic Nerve Head
Sigal
IOVS 2009;50:2785-2795.
ABSTRACT | FULL TEXT  

The association between retinal vein ophthalmodynamometric force change and optic disc excavation
Morgan et al.
Br J Ophthalmol 2009;93:594-596.
ABSTRACT | FULL TEXT  

Genetic Risk for Primary Open-Angle Glaucoma Determined by LMX1B Haplotypes
Park et al.
IOVS 2009;50:1522-1530.
ABSTRACT | FULL TEXT  

Primary Open-Angle Glaucoma
Kwon et al.
NEJM 2009;360:1113-1124.
FULL TEXT  

Comparison of Risk Factors for Bilateral and Unilateral Eye Involvement in Normal-Tension Glaucoma
Kim and Kim
IOVS 2009;50:1215-1220.
ABSTRACT | FULL TEXT  

Biomechanical Effects of Intraocular Pressure Elevation on Optic Nerve/Lamina Cribrosa before and after Peripapillary Scleral Collagen Cross-Linking
Thornton et al.
IOVS 2009;50:1227-1233.
ABSTRACT | FULL TEXT  

Predicting Progressive Glaucomatous Optic Neuropathy Using Baseline Standard Automated Perimetry Data
Demirel et al.
IOVS 2009;50:674-680.
ABSTRACT | FULL TEXT  

Ocular Hypertension Treatment Study
Higginbotham
Arch Ophthalmol 2009;127:213-215.
FULL TEXT  

Preventing Glaucoma in a High-Risk Population: Impact and Observations of the Ocular Hypertension Treatment Study
Rhee
Arch Ophthalmol 2009;127:216-218.
FULL TEXT  

Can Diabetes Be Good for Glaucoma? Why Can't We Believe Our Own Eyes (or Data)?
Quigley
Arch Ophthalmol 2009;127:227-229.
FULL TEXT  

Corneal Biomechanical Properties and Retinal Vascular Caliber in Children
Lim et al.
IOVS 2009;50:121-125.
ABSTRACT | FULL TEXT  

Prevalence of exfoliation syndrome in central Sri Lanka: the Kandy Eye Study
Rudkin et al.
Br J Ophthalmol 2008;92:1595-1598.
ABSTRACT | FULL TEXT  

Manganese-Enhanced MRI of the DBA/2J Mouse Model of Hereditary Glaucoma
Calkins et al.
IOVS 2008;49:5083-5088.
ABSTRACT | FULL TEXT  

Sleep Disorders and the Eye
Waller et al.
Mayo Clin Proc. 2008;83:1251-1261.
ABSTRACT | FULL TEXT  

Corneal biomechanics, thickness and optic disc morphology in children with optic disc tilt
Lim et al.
Br J Ophthalmol 2008;92:1461-1466.
ABSTRACT | FULL TEXT  

Wearing swimming goggles can elevate intraocular pressure
Morgan et al.
Br J Ophthalmol 2008;92:1218-1221.
ABSTRACT | FULL TEXT  

Corneal Hysteresis but Not Corneal Thickness Correlates with Optic Nerve Surface Compliance in Glaucoma Patients
Wells et al.
IOVS 2008;49:3262-3268.
ABSTRACT | FULL TEXT  

Canadian Glaucoma Study: 2. Risk Factors for the Progression of Open-angle Glaucoma
Chauhan et al.
Arch Ophthalmol 2008;126:1030-1036.
ABSTRACT | FULL TEXT  

Finding Risks for Glaucoma
Brandt
Arch Ophthalmol 2008;126:1138-1139.
FULL TEXT  

Dynamic Contour Tonometry in Comparison to Intracameral IOP Measurements
Boehm et al.
IOVS 2008;49:2472-2477.
ABSTRACT | FULL TEXT  

Comparison of HRT-3 Glaucoma Probability Score and Subjective Stereophotograph Assessment for Prediction of Progression in Glaucoma
Alencar et al.
IOVS 2008;49:1898-1906.
ABSTRACT | FULL TEXT  

Caffeine Consumption and the Risk of Primary Open-Angle Glaucoma: A Prospective Cohort Study
Kang et al.
IOVS 2008;49:1924-1931.
ABSTRACT | FULL TEXT  

Diabetes and Glaucoma
Kass et al.
Arch Ophthalmol 2008;126:746-747.
FULL TEXT  

Mitochondrial Complex I Defect Induces ROS Release and Degeneration in Trabecular Meshwork Cells of POAG Patients: Protection by Antioxidants
He et al.
IOVS 2008;49:1447-1458.
ABSTRACT | FULL TEXT  

Effectiveness and Safety of Dorzolamide-Timolol Alone or Combined with Latanoprost in Open-Angle Glaucoma or Ocular Hypertension
Lesk et al.
The Annals of Pharmacotherapy 2008;42:498-504.
ABSTRACT | FULL TEXT  

Central Corneal Thickness and Optic Disc Hemorrhages: The Beijing Eye Study
Xu et al.
Arch Ophthalmol 2008;126:435-436.
FULL TEXT  

Tissue Transglutaminase Expression and Activity in Normal and Glaucomatous Human Trabecular Meshwork Cells and Tissues
Tovar-Vidales et al.
IOVS 2008;49:622-628.
ABSTRACT | FULL TEXT  

Misclassification: Who Really Lives in This Neighborhood?
Sommer
Arch Ophthalmol 2008;126:265-266.
FULL TEXT  

Is a History of Diabetes Mellitus Protective Against Developing Primary Open-angle Glaucoma?
Gordon et al.
Arch Ophthalmol 2008;126:280-281.
FULL TEXT  

Estimating the Rate of Progressive Visual Field Damage in Those with Open-Angle Glaucoma, from Cross-Sectional Data
Broman et al.
IOVS 2008;49:66-76.
ABSTRACT | FULL TEXT  

Effects of Timolol on MYOC, OPTN, and WDR36 RNA Levels
Rozsa et al.
Arch Ophthalmol 2008;126:86-93.
ABSTRACT | FULL TEXT  

Repeatability and Reproducibility of Pachymetric Mapping with Visante Anterior Segment Optical Coherence Tomography
Mohamed et al.
IOVS 2007;48:5499-5504.
ABSTRACT | FULL TEXT  

The accuracy of accredited glaucoma optometrists in the diagnosis and treatment recommendation for glaucoma
Azuara-Blanco et al.
Br J Ophthalmol 2007;91:1639-1643.
ABSTRACT | FULL TEXT  

Ocular blood flow in glaucoma: the need for further clinical evidence and patient outcomes research
Stewart et al.
Br J Ophthalmol 2007;91:1263-1264.
FULL TEXT  

A comparison of global indices between the Medmont Automated Perimeter and the Humphrey Field Analyzer
Landers et al.
Br J Ophthalmol 2007;91:1285-1287.
ABSTRACT | FULL TEXT  

Novel pressure-to-cornea index in glaucoma
Iliev et al.
Br J Ophthalmol 2007;91:1364-1368.
ABSTRACT | FULL TEXT  

The amount of intraocular pressure rise during pharmacological pupillary dilatation is an indicator of the likelihood of future progression of glaucoma
Siam et al.
Br J Ophthalmol 2007;91:1170-1172.
ABSTRACT | FULL TEXT  

Genetic Contributions to Glaucoma: Heritability of Intraocular Pressure, Retinal Nerve Fiber Layer Thickness, and Optic Disc Morphology
van Koolwijk et al.
IOVS 2007;48:3669-3676.
ABSTRACT | FULL TEXT  

Effects of Topical Administration of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Ocular Tissues in Rabbits and Monkeys
Tokushige et al.
IOVS 2007;48:3216-3222.
ABSTRACT | FULL TEXT  

Evaluation of ocular surface temperature and retrobulbar haemodynamics by infrared thermography and colour Doppler imaging in patients with glaucoma
Galassi et al.
Br J Ophthalmol 2007;91:878-881.
ABSTRACT | FULL TEXT  

Role of Corneal Elasticity in Damping of Intraocular Pressure
Johnson et al.
IOVS 2007;48:2540-2544.
ABSTRACT | FULL TEXT  

Effect of Central Corneal Thickness on Dynamic Contour Tonometry and Goldmann Applanation Tonometry in Primary Open-angle Glaucoma
Grieshaber et al.
Arch Ophthalmol 2007;125:740-744.
ABSTRACT | FULL TEXT  

Comparison of Initial Intraocular Pressure Response With Topical beta-Adrenergic Antagonists and Prostaglandin Analogues in African American and White Individuals in the Ocular Hypertension Treatment Study
Mansberger et al.
Arch Ophthalmol 2007;125:454-459.
ABSTRACT | FULL TEXT  

Retinal vein pulsation predicts increasing optic disc excavation
Nicolela
Br J Ophthalmol 2007;91:405-406.
FULL TEXT  

Recent advances in ophthalmic anterior segment imaging: a new era for ophthalmic diagnosis?
Konstantopoulos et al.
Br J Ophthalmol 2007;91:551-557.
ABSTRACT | FULL TEXT  

Value of retinal vein pulsation characteristics in predicting increased optic disc excavation
Balaratnasingam et al.
Br J Ophthalmol 2007;91:441-444.
ABSTRACT | FULL TEXT  

Comparing Multifocal VEP and Standard Automated Perimetry in High-Risk Ocular Hypertension and Early Glaucoma
Fortune et al.
IOVS 2007;48:1173-1180.
ABSTRACT | FULL TEXT  

Non-invasive vascular impedance measures demonstrate ocular vasoconstriction during isometric exercise
Morgan and Hosking
Br J Ophthalmol 2007;91:385-390.
ABSTRACT | FULL TEXT  

Bone Morphogenetic Protein-7 Is an Antagonist of Transforming Growth Factor-{beta}2 in Human Trabecular Meshwork Cells
Fuchshofer et al.
IOVS 2007;48:715-726.
ABSTRACT | FULL TEXT  

Circadian Fluctuation of Mean Ocular Perfusion Pressure Is a Consistent Risk Factor for Normal-Tension Glaucoma
Choi et al.
IOVS 2007;48:104-111.
ABSTRACT | FULL TEXT  

Evaluation of the beta2-Adrenergic Receptor Gene as a Candidate Glaucoma Gene in 2 Ancestral Populations
McLaren et al.
Arch Ophthalmol 2007;125:105-111.
ABSTRACT | FULL TEXT  

Reduced Human and Murine Corneal Thickness in an Axenfeld-Rieger Syndrome Subtype
Asai-Coakwell et al.
IOVS 2006;47:4905-4909.
ABSTRACT | FULL TEXT  

Relationship Between Central Corneal Thickness and Changes of Optic Nerve Head Topography and Blood Flow After Intraocular Pressure Reduction in Open-angle Glaucoma and Ocular Hypertension.
Lesk et al.
Arch Ophthalmol 2006;124:1568-1572.
ABSTRACT | FULL TEXT  

A topical nitric oxide-releasing dexamethasone derivative: effects on intraocular pressure and ocular haemodynamics in a rabbit glaucoma model
Galassi et al.
Br J Ophthalmol 2006;90:1414-1419.
ABSTRACT | FULL TEXT  

Aqueous humor outflow: what do we know? Where will it lead us?
Fautsch et al.
IOVS 2006;47:4181-4187.
FULL TEXT  

Ocular Response Analyzer versus Goldmann Applanation Tonometry for Intraocular Pressure Measurements.
Martinez-de-la-Casa et al.
IOVS 2006;47:4410-4414.
ABSTRACT | FULL TEXT  

Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study.
Levine et al.
IOVS 2006;47:3896-3903.
ABSTRACT | FULL TEXT  

Optic disc and visual field progression in ocular hypertensive subjects: detection rates, specificity, and agreement.
Strouthidis et al.
IOVS 2006;47:2904-2910.
ABSTRACT | FULL TEXT  

Effects of Topical Hypotensive Drugs on Circadian IOP, Blood Pressure, and Calculated Diastolic Ocular Perfusion Pressure in Patients with Glaucoma.
Quaranta et al.
IOVS 2006;47:2917-2923.
ABSTRACT | FULL TEXT  

Disease Severity of Familial Glaucoma Compared With Sporadic Glaucoma
Wu et al.
Arch Ophthalmol 2006;124:950-954.
ABSTRACT | FULL TEXT  

Proteomics implicates peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis.
Bhattacharya et al.
IOVS 2006;47:2508-2514.
ABSTRACT | FULL TEXT  

A statistical approach to the evaluation of covariate effects on the receiver operating characteristic curves of diagnostic tests in glaucoma.
Medeiros et al.
IOVS 2006;47:2520-2527.
ABSTRACT | FULL TEXT  

Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma.
Barkana et al.
Arch Ophthalmol 2006;124:793-797.
ABSTRACT | FULL TEXT  

Longitudinal changes in central corneal thickness and their relation to glaucoma status: an 8 year follow up study
Weizer et al.
Br J Ophthalmol 2006;90:732-736.
ABSTRACT | FULL TEXT  

Effect of moderate intraocular pressure changes on topographic measurements with confocal scanning laser tomography in patients with glaucoma.
Nicolela et al.
Arch Ophthalmol 2006;124:633-640.
ABSTRACT | FULL TEXT  

The future of glaucoma clinics
Morley and Murdoch
Br J Ophthalmol 2006;90:640-645.
ABSTRACT | FULL TEXT  

Microarray analysis of retinal gene expression in the DBA/2J model of glaucoma.
Steele et al.
IOVS 2006;47:977-985.
ABSTRACT | FULL TEXT  

Quantitative Correlation of Optic Nerve Pathology with Ocular Pressure and Corneal Thickness in the DBA/2 Mouse Model of Glaucoma.
Inman et al.
IOVS 2006;47:986-996.
ABSTRACT | FULL TEXT  

A Large GLC1C Greek Family with a Myocilin T377M Mutation: Inheritance and Phenotypic Variability
Petersen et al.
IOVS 2006;47:620-625.
ABSTRACT | FULL TEXT  

Detection of psychophysical and structural injury in eyes with glaucomatous optic neuropathy and normal standard automated perimetry.
Bagga et al.
Arch Ophthalmol 2006;124:169-176.
ABSTRACT | FULL TEXT  

Anterior Optic Nerve Capillary Blood Flow Response to Diurnal Variation of Mean Ocular Perfusion Pressure in Early Untreated Primary Open-Angle Glaucoma
Sehi et al.
IOVS 2005;46:4581-4587.
ABSTRACT | FULL TEXT  

Regulation of Glucocorticoid Responsiveness in Glaucomatous Trabecular Meshwork Cells by Glucocorticoid Receptor-{beta}
Zhang et al.
IOVS 2005;46:4607-4616.
ABSTRACT | FULL TEXT  

The relative effects of corneal thickness and age on Goldmann applanation tonometry and dynamic contour tonometry
Kotecha et al.
Br J Ophthalmol 2005;89:1572-1575.
ABSTRACT | FULL TEXT  

Factors Influencing Optic Nerve Head Biomechanics
Sigal et al.
IOVS 2005;46:4189-4199.
ABSTRACT | FULL TEXT  

Validation of a Predictive Model to Estimate the Risk of Conversion From Ocular Hypertension to Glaucoma
Medeiros et al.
Arch Ophthalmol 2005;123:1351-1360.
ABSTRACT | FULL TEXT  

Baseline Topographic Optic Disc Measurements Are Associated With the Development of Primary Open-Angle Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study
Zangwill et al.
Arch Ophthalmol 2005;123:1188-1197.
ABSTRACT | FULL TEXT  

Glaucoma: Macrocosm to Microcosm The Friedenwald Lecture
Quigley
IOVS 2005;46:2663-2670.
FULL TEXT  

Central corneal thickness and progression of the visual field and optic disc in glaucoma
Chauhan et al.
Br J Ophthalmol 2005;89:1008-1012.
ABSTRACT | FULL TEXT  

Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials
Maier et al.
BMJ 2005;331:134.
ABSTRACT | FULL TEXT  

Incorporating the Results of the Ocular Hypertension Treatment Study Into Clinical Practice
Kass et al.
Arch Ophthalmol 2005;123:1021-1022.
FULL TEXT  

A comparison of four methods of tonometry: method agreement and interobserver variability
Tonnu et al.
Br J Ophthalmol 2005;89:847-850.
ABSTRACT | FULL TEXT  

The influence of central corneal thickness and age on intraocular pressure measured by pneumotonometry, non-contact tonometry, the Tono-Pen XL, and Goldmann applanation tonometry
Tonnu et al.
Br J Ophthalmol 2005;89:851-854.
ABSTRACT | FULL TEXT  

Need for Eye Care Among Older Adults With Diabetes Mellitus in Fee-for-Service and Managed Medicare
Brown et al.
Arch Ophthalmol 2005;123:669-675.
ABSTRACT | FULL TEXT  

A novel index for predicting intraocular pressure reduction following cataract surgery
Issa et al.
Br J Ophthalmol 2005;89:543-546.
ABSTRACT | FULL TEXT  

Central Corneal Thickness Correlated with Glaucoma Damage and Rate of Progression
Jonas et al.
IOVS 2005;46:1269-1274.
ABSTRACT | FULL TEXT  

Central Corneal Thickness and Thickness of the Lamina Cribrosa in Human Eyes
Jonas and Holbach
IOVS 2005;46:1275-1279.
ABSTRACT | FULL TEXT  

The Influence of Various Substances on the Biomechanical Behavior of Lamina Cribrosa and Peripapillary Sclera
Spoerl et al.
IOVS 2005;46:1286-1290.
ABSTRACT | FULL TEXT  

Relative Change in Diurnal Mean Ocular Perfusion Pressure: A Risk Factor for the Diagnosis of Primary Open-Angle Glaucoma
Sehi et al.
IOVS 2005;46:561-567.
ABSTRACT | FULL TEXT  

The Gradient of Retinal Functional Changes during Acute Intraocular Pressure Elevation
Bui et al.
IOVS 2005;46:202-213.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.